Early evidence that enzyme inducers can reduce serum concentrations of tamoxifen and endoxifen appeared decades ago
A 2025 study found irregular menstrual cycles dropped from 86% to 32% on tirzepatide, with significant improvement in insulin resistance.[10] A real-world study presented at ObesityWeek 2025 found over 90% of PCOS patients on tirzepatide hit at least 10% weight loss within 10 months.[11] Theres even a registered clinical trial specifically testing tirzepatide for PCOS
Furthermore, it is hypothesised that the decline in ATP levels in instances of oxidative damage is associated with a decrease in ATP production and an increase in ATP consumption
Finally, organic silica hydrates, renews and regenerates cells and improves collagen synthesis
Understanding these distinctions can help patients and clinicians make more informed treatment decisions
After scrapping a Biden-era plan to cover obesity drugs in early 2025, the Trump administration reversed course: it struck deals with Novo Nordisk and Eli Lilly in November 2025 to cut GLP-1 prices, and a voluntary Medicare demonstration begins July 1, 2026 that lets participating drug plans cover GLP-1s for weight loss with a $50 monthly copay
.webp)
